Creative Medical Technology Holdings Inc. (Nasdaq: CELZ)

The Degenerative Disc Disease (DDD) market in the US alone reached an estimated $3.6 billion in 2023, with over 13 million diagnosed cases. By 2034, this number is projected to rise significantly, driven by factors like aging populations and lifestyle shifts. Creative Medical Technology Holdings Inc. (Nasdaq: CELZ) is proud to be part of the evolving treatment landscape, contributing to innovative therapies that prioritize patient outcomes. With promising developments in regenerative medicine and minimally invasive treatments, the future of DDD management is focused on enhancing quality of life and bridging the gap between conservative care and surgical options. https://lnkd.in/eE5Hhz3z #DegenerativeDiscDisease #RegenerativeMedicine #InnovationInHealth #CreativeMedicalTechnology #HealthcareTrends

#ClinicalTrials #RegenerativeMedicine #BiotechInnovation #Healthcare #ChronicPain #LowerBackPain #ADAPT #NASDAQ #CELZ Creative Medical Technology Holdings Inc. (Nasdaq: CELZ)

Creative Medical Technology Holdings Inc. (Nasdaq: CELZ) Advances #FDA Cleared #ADAPT Clinical Trial with #Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment ? Creative Medical Technology Holdings, Inc. (#NASDAQ: #CELZ), a #biotechnology leader in #regenerative #medicine, is pleased to announce the successful completion of an independent interim safety review by the Data Safety Monitoring Board (#DSMB) for its ADAPT clinical trial. The trial evaluated #CELZ-201, a novel therapeutic perinatal tissue derived cell product, designed to treat #chronic #lower #back #pain associated with degenerative disc disease. ? https://lnkd.in/eRZd6RXq #creativemedical #celz #nasdaq #biotech

Creative Medical Technology Holdings Inc. (Nasdaq: CELZ) honors the strength and dedication of our veterans. Today, we recognize their sacrifices and express our gratitude for their service in protecting our freedoms. ? Happy #Veterans Day!

The hidden dangers of prediabetes ? Not only can the condition lead to diabetes, but it also increases your risk for cardio-vascular, kidney, and liver disease. ? https://lnkd.in/ePRuM_bD ? The article highlights the significant health risks associated with prediabetes and its progression to type 1 diabetes, a condition that remains challenging to manage. Advances in regenerative medicine, such as the CELZ-201 treatment being studied in the CREATE-1 clinical trial, aim to address the underlying causes of type 1 diabetes. By focusing on immunomodulation and improving immune regulation, this approach seeks to provide hope for patients impacted by the disease.? ? As research progresses, efforts by Creative Medical Technology Holdings Inc. (Nasdaq: CELZ) to improve patient outcomes and manage the complications associated with diabetes continue to grow in importance.? ? For more information on the CELZ-201 trial, visit?https://lnkd.in/eZ8FAwYB #creativemedical #celz #nasdaq #biotech

Creative Medical Technology Holdings Inc. (Nasdaq: CELZ) is advancing innovative solutions to address one of the most widespread health issues—chronic lower back pain. Our ADAPT clinical trial leverages CELZ-201-DDT for the treatment of Degenerative Disc Disease, targeting the root causes of pain rather than merely managing symptoms. ? With 70% of adults experiencing lower back pain in their lifetime, current treatments often fail to address the underlying degeneration of intervertebral discs. ADAPT offers a regenerative approach that aims to change?this?narrative, providing hope for improved quality of life. ? Learn more about our progress -?https://lnkd.in/df9jcNii #creativemedical #celz #biotech

Creative Medical Technology Holdings Inc. (Nasdaq: CELZ) Airing on CNBC and Fox Business throughout October ? CELZ_30Sec_V3 (youtube.com)

Creative Medical Technology Holdings Inc. (Nasdaq: CELZ) is at the forefront of #biotech innovation, leveraging #AI-driven diagnostics and personalized #stem cell therapies to address complex medical challenges, including #biologic and #chemical exposure. By combining cutting-edge #technology with a validated #iPSC program, the company is not only revolutionizing patient care but also optimizing resource efficiency and regulatory compliance, positioning itself as a leader in #regenerative medicine for investors and industry professionals alike. https://lnkd.in/eSHiT2mZ #creativemedical #celz #nasdaq #biotech

September is Spinal Cord Injury Awareness Month, a time to raise awareness for the countless individuals affected by spinal cord injuries. ? Creative Medical Technology Holdings Inc. (Nasdaq: CELZ) is a biotechnology company committed to improving patient lives via a regenerative approach to immunology, endocrinology, urogynecology, and orthopedics. ? #SpinalCordInjuryAwarenessMonth #RegenerativeMedicine #PatientCare #InnovativeHealth #MedicalResearch #CreativeMedicalTech #SpinalCordInjury #Recovery

September is Pain Awareness Month, a reminder of the millions impacted by chronic pain.? ? At Creative Medical Technology Holdings Inc. (Nasdaq: CELZ), we're addressing this challenge through our #ADAPT clinical trial, which targets chronic lower back pain caused by Degenerative Disc Disease. Our innovative regenerative approach, using CELZ-201-DDT, aims to provide lasting relief by treating the root cause, not just the symptoms.? ? We stand with those living with pain and are committed to finding better solutions for relief and recovery.? ? #PainAwarenessMonth #ChronicPain #RegenerativeMedicine #LowerBackPain #DegenerativeDiscDisease #PatientCare #InnovativeHealth #MedicalResearch #CreativeMedicalTech